SCHEMBL4994532

SCHEMBL4994532

O=C(O)CNC(=O)c1c(O)nc(C2CCCCC2)n(-c2ccccc2F)c1=O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 10/20 0.43
OGFOD1 Q8N543 1/20 0.43
EGLN2 Q96KS0 1/20 0.43
EGLN3 Q9H6Z9 1/20 0.43
HIF1AN Q9NWT6 1/20 0.43
APLNR P35414 1/20 0.41
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
OGFRL1 Q5TC84 1/20 0.40
ALDH1A1 P00352 1/20 0.38
BBOX1 O75936 1/20 0.38
ASPH Q12797 1/20 0.38
KDM8 Q8N371 1/20 0.38
THRB P10828 1/20 0.38
MDM2 Q00987 1/20 0.37
USP5 P45974 1/20 0.37
HIF1A Q16665 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4988740 0.93 EGLN1 (0.41) EGLN1OGFOD1EGLN2EGLN3HIF1AN
SCHEMBL4995450 0.89 EGLN3 (0.43) EGLN1OGFOD1EGLN2EGLN3HIF1AN
SCHEMBL4737006 0.88 EGLN1 (0.52) EGLN1OGFOD1EGLN2EGLN3HIF1AN
SCHEMBL4994439 0.86 EGLN3 (0.44) EGLN1OGFOD1EGLN2EGLN3HIF1AN
SCHEMBL4992285 0.85 EGLN1 (0.54) EGLN1OGFOD1EGLN2EGLN3HIF1AN
SCHEMBL4991812 0.84 EGLN1 (0.44) EGLN1OGFOD1EGLN2EGLN3HIF1AN
SCHEMBL4993614 0.83 EGLN1 (0.44) EGLN1OGFOD1EGLN2EGLN3HIF1AN
SCHEMBL4994536 0.83 EGLN1 (0.38) EGLN1OGFOD1EGLN2EGLN3HIF1AN
SCHEMBL4988793 0.82 EGLN3 (0.46) EGLN1OGFOD1EGLN2EGLN3HIF1AN
SCHEMBL5000019 0.82 EGLN1 (0.43) EGLN1OGFOD1EGLN2EGLN3HIF1AN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US claimed
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 EGLN1 5/4885OGFOD1 15/4885EGLN2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.